Comment on “Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial”

[...]the withdrawal rate was high in the brodalumab treatment group in this study [1], with 13 out of 63 patients sufering from discontinuation of the drug before 16 weeks, which may have biased the results of the trial to some extent. [...]a plethora of clinical reports have documented the occurren...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical dermatology 2024-11, Vol.25 (6), p.1023-1024
Main Authors: Wang, Lu-Ying, Ding, Yi-Hang, Hou, Xiu-Juan, Li, Chen
Format: Article
Language:English
Subjects:
Alopecia
Baldness
Chen Li
Clinical trials
Conflicts of interest
Cytokines
Dermatology
Infections
Letter to the Editor
Medicine
Medicine & Public Health
Monoclonal antibodies
Pathogenesis
Pharmacology/Toxicology
Pharmacotherapy
Psoriasis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]the withdrawal rate was high in the brodalumab treatment group in this study [1], with 13 out of 63 patients sufering from discontinuation of the drug before 16 weeks, which may have biased the results of the trial to some extent. [...]a plethora of clinical reports have documented the occurrence of paradoxical cutaneous manifestations after the administration of IL-17 inhibitors. [...]its skin inflammatory response might be more prone to be mediated by cytokines such as IL-4 and IL-13 and have less connection with IL-17 and TNF-α.
ISSN:1175-0561
1179-1888
1179-1888
DOI:10.1007/s40257-024-00895-8